Le Registre des lobbyistes
Actifs
-
Dernière mise à jour le :
2025-01-01
| Objets | Détails | Catégories |
|---|---|---|
|
Commerce international,
Impôts et finances,
Industrie,
Marchés publics,
Propriété intellectuelle,
Recherche et développement,
Relations fédérales-provinciales,
Santé
|
Advocacy on the creation of the Health Emergency Readiness Canada (HERC) Agency
|
Politique ou Programme
|
|
Commerce international,
Propriété intellectuelle
|
Advocacy on the proposed Regulations Amending the Patent Rules and Certain Regulations Made Under the Patent Act which were published for consultation in Canada Gazette Part I (CGI) on May 18, 2024.1 Share concerns with Canada’s implementation of a patent term adjustment (PTA) system that is not compliant with its trade obligations, as it does not provide a meaningful remedy to patentees who are impacted by unreasonable patent office delays.
|
Proposition législative, Projet de loi ou résolution,
Règlement
|
|
Budget,
Santé
|
Advocacy to maintain and increase funding for the National Immunization Strategy and discussions on vaccine procurement.
|
Politique ou Programme,
Subvention, Contribution ou autre avantage financier
|
|
Affaires étrangères,
Commerce international,
Impôts et finances,
Marchés publics,
Recherche et développement,
Relations fédérales-provinciales,
Santé
|
Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods
|
Politique ou Programme,
Proposition législative, Projet de loi ou résolution,
Règlement
|
|
Commerce international,
Santé
|
Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States.
|
Politique ou Programme,
Proposition législative, Projet de loi ou résolution,
Règlement
|
|
Commerce international,
Industrie,
Propriété intellectuelle,
Recherche et développement,
Santé
|
Contribution to the Government Public consultations on Canada-United States-Mexico Agreement to inform Canada’s priorities in preparation for the first joint review of CUSMA by Canada, the United States and Mexico in 2026 and ahead of Canada’s chairing of the 5th meeting of the CUSMA Free Trade Commission, in 2025.
|
Politique ou Programme,
Proposition législative, Projet de loi ou résolution,
Règlement
|
|
Commerce international,
Propriété intellectuelle,
Santé
|
Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver and the World Health Organization pandemic treaty proposal
|
Politique ou Programme,
Proposition législative, Projet de loi ou résolution,
Règlement
|
|
Marchés publics,
Santé
|
Discussions on the procurement of a COVID19 vaccine and therapy
|
Subvention, Contribution ou autre avantage financier
|
|
Industrie,
Santé
|
Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.
|
Politique ou Programme,
Règlement
|
|
Marchés publics,
Santé
|
Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
|
Politique ou Programme
|
|
Santé
|
Health Canada’s policies, program and guidelines related to the management, prevention, mitigation and notification of drug shortages
|
Politique ou Programme,
Proposition législative, Projet de loi ou résolution,
Règlement
|
|
Santé
|
Monitoring and engaging on the Government’s commitment to create a national strategy for rare diseases; the Canadian Drug Agency; and C64, An Act to Implement pharmacare.
|
Politique ou Programme,
Proposition législative, Projet de loi ou résolution,
Règlement
|
|
Commerce international,
Industrie,
Santé
|
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy
|
Politique ou Programme,
Règlement
|
|
Santé
|
Patented Medicine Prices Review Board (PMPRB) amendments to the Patented Medicines Regulations and the related proposed guidelines.
|
Politique ou Programme,
Règlement
|
|
Santé
|
Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.
|
Politique ou Programme,
Règlement
|
|
Industrie
|
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
|
Politique ou Programme
|
| Objets | Détails | Catégories |
|---|---|---|
|
Marchés publics
|
Monitoring and engaging the Government and Parliamentarians on the House of Commons Standing Committee on Public Accounts (PACP) motion related to the discloser on vaccine contracts
|
Proposition législative, Projet de loi ou résolution
|
Techniques de communication déjà utilisées ou qui seront utilisées au cours de l'engagement :
| Date | TCPD, Titre du poste | Institution gouvernementale | Objets |
|---|---|---|
| 2025-03-04 |
|
Affaires étrangères, Commerce international, Impôts et finances, Marchés publics, Recherche et développement, Relations fédérales-provinciales, Santé |
| 2024-09-26 |
|
Affaires étrangères, Commerce international, Impôts et finances, Industrie, Petites entreprises, Recherche et développement, Santé, Sciences et technologies |
| 2024-09-24 |
|
Industrie, Santé |
| 2024-09-24 |
|
Industrie, Recherche et développement, Relations fédérales-provinciales, Santé |
| 2024-09-23 |
|
Commerce international, Impôts et finances, Propriété intellectuelle, Questions constitutionnelles, Questions touchant les consommateurs, Recherche et développement, Relations fédérales-provinciales, Santé, Sciences et technologies |
| 2024-09-23 |
|
Affaires étrangères, Commerce international, Impôts et finances, Industrie, Petites entreprises, Propriété intellectuelle, Questions touchant les consommateurs, Recherche et développement, Relations fédérales-provinciales, Santé, Sciences et technologies |
| 2024-08-28 |
|
Commerce international, Propriété intellectuelle |
| 2024-05-23 |
|
Commerce international, Impôts et finances, Industrie, Propriété intellectuelle, Recherche et développement, Relations fédérales-provinciales, Santé, Sciences et technologies |
| 2024-05-21 |
|
Commerce international, Industrie, Santé |